Can Tremfya Cause Thrombocytopenia?
Thrombocytopenia is not a recognized adverse effect of Tremfya (guselkumab) based on FDA labeling and extensive clinical trial data. The FDA drug label does not list thrombocytopenia as an adverse reaction, and comprehensive pooled safety analyses of over 10,000 patient-years of exposure have not identified this as a safety signal 1.
Evidence from FDA Labeling and Clinical Trials
The FDA-approved prescribing information for Tremfya details adverse reactions from pooled clinical trials in 1,441 subjects with psoriasis through 16 weeks and extended follow-up through 48 weeks. Thrombocytopenia is notably absent from all adverse reaction tables and safety summaries 1.
Documented Adverse Reactions Include:
- Upper respiratory infections (14.3%)
- Headache (4.6%)
- Injection site reactions (4.5%)
- Arthralgia (2.7%)
- Elevated liver enzymes (2.6%)
- Infections (23% overall)
Psoriatic Arthritis Population
In psoriatic arthritis trials with 748 subjects on Tremfya, the safety profile remained consistent with psoriasis studies, with the addition of:
- Bronchitis (1.6-2.9%)
- Neutrophil count decreased (0.3-1.6%) - notably neutropenia, not thrombocytopenia 1
The neutrophil decreases were mild, transient, not associated with infection, and did not lead to discontinuation.
Long-Term Safety Data
A comprehensive integrated analysis of 4,399 guselkumab-treated patients across 11 phase II/III studies with 10,787 patient-years of follow-up (up to 5 years) found no signal for thrombocytopenia 2. Similarly, a pooled analysis of 2,891 patients with psoriasis followed for 8,662 patient-years showed consistent safety without thrombocytopenia reported 3.
Baseline Monitoring Recommendations
The 2019 AAD-NPF guidelines for biologics in psoriasis recommend baseline CBC monitoring before initiating IL-23 inhibitors like guselkumab 4. However, this is standard practice for all biologics and does not reflect a specific concern for thrombocytopenia with guselkumab—rather, it establishes baseline values for general safety monitoring.
Clinical Implications
If thrombocytopenia develops in a patient on Tremfya, alternative etiologies should be investigated as this is not a known drug effect. Consider:
- Concurrent medications
- Underlying autoimmune conditions
- Viral infections
- Other hematologic disorders
The absence of thrombocytopenia across extensive clinical trial experience (including over 8,600 patient-years of exposure) provides strong reassurance that this is not a drug-related adverse effect 2, 3.